Non-Current Liabilities
Contingent Consideration Liability (Non-Current)
Amgen Contingent Consideration Liability (Non-Current) increased by 7.5% to $173M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 66.3%, from $104M to $173M. Over 5 years (FY 2020 to FY 2025), Contingent Consideration Liability (Non-Current) shows an upward trend with a 37.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
First reportedQ4 2016
Last reportedQ1 2026Apr 30, 2026
Metric ID:
contingent_consideration_liability_noncurrentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $48M | $35M | $342M | $330M | $310M | $302M | $270M | $273M | $248M | $98M | $96M | $96M | $107M | $112M | $106M | $104M | $90M | $95M | $161M | $173M |
| QoQ Change | — | -27.1% | +877.1% | -3.5% | -6.1% | -2.6% | -10.6% | +1.1% | -9.2% | -60.5% | -2.0% | +0.0% | +11.5% | +4.7% | -5.4% | -1.9% | -13.5% | +5.6% | +69.5% | +7.5% |
| YoY Change | — | — | — | — | +545.8% | +762.9% | -21.1% | -17.3% | -20.0% | -67.5% | -64.4% | -64.8% | -56.9% | +14.3% | +10.4% | +8.3% | -15.9% | -15.2% | +51.9% | +66.3% |
Range$35M – $342M
CAGR+31.0%
Avg YoY Growth+69.8%
Median YoY Growth-15.5%
Current Streak3 quarters growth
Contingent Consideration Liability (Non-Current) at Other Companies
Frequently Asked Questions
- What is Amgen's contingent consideration liability (non-current)?
- Amgen (AMGN) reported contingent consideration liability (non-current) of $173M in Q1 2026.
- How has Amgen's contingent consideration liability (non-current) changed year-over-year?
- Amgen's contingent consideration liability (non-current) increased by 66.3% year-over-year, from $104M to $173M.
- What is the long-term trend for Amgen's contingent consideration liability (non-current)?
- Over 5 years (2020 to 2025), Amgen's contingent consideration liability (non-current) has grown at a 37.3% compound annual growth rate (CAGR), from $33M to $161M.